Avalo Therapeutics Management
Management criteria checks 2/4
Avalo Therapeutics' CEO is Garry Neil, appointed in Feb 2022, has a tenure of 2.83 years. total yearly compensation is $1.08M, comprised of 44.2% salary and 55.8% bonuses, including company stock and options. directly owns 0.001% of the company’s shares, worth €504.85. The average tenure of the management team and the board of directors is 2.8 years and 2.8 years respectively.
Key information
Garry Neil
Chief executive officer
US$1.1m
Total compensation
CEO salary percentage | 44.2% |
CEO tenure | 2.8yrs |
CEO ownership | 0.0006% |
Management average tenure | 2.8yrs |
Board average tenure | 2.8yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Sep 30 2024 | n/a | n/a | -US$8m |
Jun 30 2024 | n/a | n/a | -US$19m |
Mar 31 2024 | n/a | n/a | -US$49m |
Dec 31 2023 | US$1m | US$475k | -US$32m |
Sep 30 2023 | n/a | n/a | -US$33m |
Jun 30 2023 | n/a | n/a | -US$25m |
Mar 31 2023 | n/a | n/a | -US$30m |
Dec 31 2022 | US$1m | US$469k | -US$42m |
Sep 30 2022 | n/a | n/a | -US$51m |
Jun 30 2022 | n/a | n/a | -US$72m |
Mar 31 2022 | n/a | n/a | -US$76m |
Dec 31 2021 | US$1m | US$423k | -US$84m |
Sep 30 2021 | n/a | n/a | -US$81m |
Jun 30 2021 | n/a | n/a | -US$77m |
Mar 31 2021 | n/a | n/a | -US$73m |
Dec 31 2020 | US$3m | US$373k | -US$64m |
Compensation vs Market: Garry's total compensation ($USD1.08M) is above average for companies of similar size in the German market ($USD468.18K).
Compensation vs Earnings: Garry's compensation has been consistent with company performance over the past year.
CEO
Garry Neil (70 yo)
2.8yrs
Tenure
US$1,075,362
Compensation
Dr. Garry A. Neil, M.D., serves as the Member of Scientific Advisory Board of Rapafusyn Research And Development, Inc. Dr. Garry serves as Independent Director of Celldex Therapeutics, Inc. since June 16,...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Chairman of the Board | 2.8yrs | US$1.08m | 0.00057% € 504.9 | |
CFO & Head of Investor relations | 2.8yrs | US$607.65k | 0.000060% € 53.1 | |
Founder and Chairman of Scientific Advisory Board | no data | no data | no data | |
Founder and Member of Scientific Advisory Board | no data | no data | no data | |
Chief Legal Officer | less than a year | no data | no data | |
Senior Vice President of Program Management | 2.9yrs | no data | no data | |
Senior Vice President of Global Regulatory Affairs & Quality Assurance | 2.9yrs | no data | no data | |
Senior Vice President of CMC & Technical Operations | 2.8yrs | no data | no data | |
Chief Medical Officer | less than a year | no data | no data |
2.8yrs
Average Tenure
59yo
Average Age
Experienced Management: C6K0's management team is considered experienced (2.8 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Chairman of the Board | 2.5yrs | US$1.08m | 0.00057% € 504.9 | |
Founder and Chairman of Scientific Advisory Board | no data | no data | no data | |
Founder and Member of Scientific Advisory Board | no data | no data | no data | |
Special Advisor & Strategic Advisory Board | 3.5yrs | US$133.94k | no data | |
Independent Director | 4.2yrs | US$60.12k | 0% € 0 | |
Member of Scientific Advisory Board | no data | no data | no data | |
Member of Scientific Advisory Board | no data | no data | no data | |
Member of Scientific Advisory Board | no data | no data | no data | |
Member of Scientific Advisory Board | no data | no data | no data | |
Independent Director | less than a year | no data | no data | |
Independent Director | less than a year | no data | no data | |
Independent Director | 3yrs | US$60.12k | 0% € 0 |
2.8yrs
Average Tenure
70yo
Average Age
Experienced Board: C6K0's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/26 02:45 |
End of Day Share Price | 2024/12/23 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Avalo Therapeutics, Inc. is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Julian Harrison | BTIG |
Louise Chen | Cantor Fitzgerald & Co. |
Raghuram Selvaraju | H.C. Wainwright & Co. |